
S&P TEST

SWOT & PESTLE.com

REGENERON SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email support@swotandpestle.com.

Company Name : Regeneron

Company Sector : Biotech, Pharmaceuticals

Operating Geography : United States, North America, Global

About the Company : Founded in 1988, Regeneron Pharmaceuticals is an American company in the biotech and pharmaceuticals space, headquartered in Tarrytown, New York. It was founded by Leonard S. Schleifer, MD, PhD who was an assistant professor at Cornell University Medical College and is also the current CEO of the company. In 1990, the company published its first paper which turned out to be the most highly cited neurobiology paper of the year. In 1991, it began trading its stock publicly on the NASDAQ (REGN). In 2000, the company began the clinical exploration of its first TRAP technology, ARCALYST (rilonacept) Injection. In 2003, it introduced its proprietary Veloci technologies through the publication of its first paper on VelociGene. In 2013, the company opened their first European business office in Dublin, Ireland. Through the years, it has also collaborated with players like Bayer and Sanofi for the production of their drugs outside the US. As of 2020, it has 7 commercial, in-house discovered medicines which have been approved by the FDA, namely – Arcalyst, Dupixent, Eylea, Kevzara, Libtayo, Praluent and Zaltrap- some of which are marketed by other leaders in the space. The company has 8,100 full-time employees as of December 2019. Apart from an office in Tarrytown, New York, the company has its facilities in Rensselaer, New York which is used for research, manufacturing, office and warehouse space.

Regeneron's mission statement reads, "To use the power of science to bring new medicines to patients over and over again."

Revenue :

US\$ 7,863.4 million – FY ended Dec 31st, 2019 (YoY growth of 17.1%)

US\$ 6,710.8 million – FY ended Dec 31st, 2018

SWOT Analysis :

The SWOT Analysis for Regeneron is given below:

| Strengths | Weaknesses |
|---|---|
| <ul style="list-style-type: none"> 1.Clinical development of products in diverse disease areas 2.Advanced technological capabilities 3.Significant investment in R&D 4.Regeneron Genetics Centre \u2013 A wholly owned subsidiary of Regeneron 5.Robust strategic alliances and collaborations 6.Multiple titles awarded to the company in recent years | <ul style="list-style-type: none"> 1.Heavy reliance on the success of the product Eylea 2.Dependence on a small number of customers |
| Opportunities | Threats |
| <ul style="list-style-type: none"> 1.Adoption of multichannel strategy 2.Constant lookout for strategic alliances with other companies | <ul style="list-style-type: none"> 1.Substantial competition from pharmaceutical, biotechnology and chemical companies 2.Sales of products dependent on other external factors 3.Commercialization of certain products depends on collaborations with other companies 4.Threat of imported products |

PESTLE Analysis :

The PESTLE Analysis for Regeneron is given below:

| Political | Economical |
|---|--|
| 1. Corporate political contributions by Regeneron | 1. Pricing Pressure from government and other third-party payers 2. Potential changes in US tax structure |
| Social | Technological |
| 1. Increasing use of social media by the pharmaceutical industry 2. A global rise in the population of geriatrics | 1. Significant investments in R&D technologies 2. Use of technology to tackle COVID-19 |
| Legal | Environmental |
| 1. Laws related to patents, trademarks and trade Secrets 2. Regulations in areas like research, development, manufacturing and marketing | 1. Pursuing environmentally sustainable practices |

Please note that our free summary reports contain the SWOT and PESTLE table contents only.

The complete report for **Regeneron** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."



S&P

SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support:
support@swotandpestle.com